CDX-014 / Celldex - LARVOL DELTA

Prevalence and clinical implications of T-cell immunoglobulin mucin type-1 (TIM-1) in multiple tumor types. (ASCO-SITC 2017) - P1/2; "The data suggest that in addition to renal and ovarian cancer, TIM-1 targeted therapy such as CDX-014 warrants exploration in patients with endometrial CCC, vaginal CCC and adeno NCSLC. These results support the ongoing first in human Ph 1/2 study in RCC and potential broader clinical development of CDX-014 in other indications."

Biosimilar • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Renal Disease

Safety and efficacy of CDX-014, an antibody-drug conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced renal cell carcinoma (ESMO 2019) - P1; "TIM-1 is a novel target in the treatment of RCC. Optimal dosing strategy of CX-104 has not yet been defined. Clinical trial identification: NCT02837991."

Clinical

Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. (PubMed, Invest New Drugs) - P1 | "Overall, CDX-014 exhibited a manageable toxicity profile and early signs of activity, supporting further evaluation of antibody-drug conjugates in patients with advanced RCC and potentially other TIM-1 expressing cancers. Trial registrationhttps://clinicaltrials.gov/ct2/show/NCT02837991 NCT02837991; July 20, 2016."

Clinical • Journal • Alopecia • Dermatopathology • Fatigue • Genito-urinary Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • KIM1 • MUC1